PriceTargets.com logo

Kinnate Biopharma - KNTE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.00
  • Forecasted Upside: 349.64%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$5.56 As of 03/24/2023 01:00 AM ET
▼ -0.2 (-3.47%)

This chart shows the closing price for KNTE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kinnate Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KNTE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KNTE

Analyst Price Target is $25.00
▲ +349.64% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Kinnate Biopharma in the last 3 months. The average price target is $25.00, with a high forecast of $33.00 and a low forecast of $8.00. The average price target represents a 349.64% upside from the last price of $5.56.

This chart shows the closing price for KNTE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Kinnate Biopharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/16/2023WedbushLower TargetOutperform$29.00 ➝ $25.00Low
3/16/2023Stifel NicolausLower TargetHold$11.00 ➝ $8.00Low
11/17/2022Stifel NicolausDowngradeBuy ➝ Hold$35.00 ➝ $11.00Low
11/16/2022WedbushLower Target$29.00Low
9/14/2022WedbushReiterated RatingOutperform$33.00Low
7/28/2022HC WainwrightInitiated CoverageBuy$33.00Low
5/24/2022The Goldman Sachs GroupLower TargetBuy$44.00 ➝ $29.00High
5/18/2022Piper SandlerLower TargetOverweight$52.00 ➝ $30.00Low
2/11/2022Stifel NicolausReiterated RatingBuy$35.00Medium
1/7/2022WedbushLower TargetOutperform ➝ Outperform$53.00 ➝ $44.00Medium
9/27/2021Jefferies Financial GroupInitiated CoverageBuy$46.00High
9/22/2021Stifel NicolausInitiated CoverageBuy$32.00Low
7/13/2021William BlairInitiated CoverageOutperformLow
12/28/2020WedbushInitiated CoverageOutperform$48.00N/A
12/28/2020SVB LeerinkInitiated CoverageOutperform$52.00N/A
12/28/2020The Goldman Sachs GroupInitiated CoverageBuy$48.00N/A
12/28/2020Piper SandlerInitiated CoverageOverweight$60.00N/A
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 4 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 4 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Kinnate Biopharma logo
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Read More

Today's Range

Now: $5.56
Low: $5.35
High: $5.70

50 Day Range

MA: $6.09
Low: $3.46
High: $7.98

52 Week Range

Now: $5.56
Low: $3.30
High: $15.86

Volume

91,893 shs

Average Volume

121,611 shs

Market Capitalization

$258.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Kinnate Biopharma?

The following equities research analysts have issued reports on Kinnate Biopharma in the last year: HC Wainwright, Piper Sandler, Stifel Nicolaus, The Goldman Sachs Group, Inc., and Wedbush.
View the latest analyst ratings for KNTE.

What is the current price target for Kinnate Biopharma?

5 Wall Street analysts have set twelve-month price targets for Kinnate Biopharma in the last year. Their average twelve-month price target is $25.00, suggesting a possible upside of 349.6%. HC Wainwright has the highest price target set, predicting KNTE will reach $33.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $8.00 for Kinnate Biopharma in the next year.
View the latest price targets for KNTE.

What is the current consensus analyst rating for Kinnate Biopharma?

Kinnate Biopharma currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KNTE will outperform the market and that investors should add to their positions of Kinnate Biopharma.
View the latest ratings for KNTE.

What other companies compete with Kinnate Biopharma?

Other companies that are similar to Kinnate Biopharma include Organogenesis, Adicet Bio, Thorne HealthTech, Silence Therapeutics and Verrica Pharmaceuticals. Learn More about companies similar to Kinnate Biopharma.

How do I contact Kinnate Biopharma's investor relations team?

The company's listed phone number is 858-299-4699 and its investor relations email address is [email protected] The official website for Kinnate Biopharma is www.kinnate.com. Learn More about contacing Kinnate Biopharma investor relations.